(Hypertension. 2002;40:304.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Departments of Internal Medicine (J.G.C., J.J.R.B., I.S.G., F.J.B.H.) and Radiology (P.M.A., P.G.R.), Hospital Universitario La Paz, Madrid, Spain; and Department of Radiology, Fundación Jiménez Díaz (E.V.M.), Madrid, Spain.
Correspondence to Dr Jorge Gómez-Cerezo, C/Oficios 16, Tres Cantos, Madrid 28760, Spain. E-mail med002708{at}saludalia.com
| Abstract |
|---|
|
|
|---|
Key Words: endothelium vasodilation arteries brachial blood pressure
| Introduction |
|---|
|
|
|---|
The prevalence of WCH has been estimated by several transversal studies between 20% and 40% among the population of mild hypertensives.3,4 Whether this group of patients has an increased cardiovascular risk similar to that of sustained essential hypertensives (SEHs), or similar to that of normotensive subjects, is an interesting and still unsolved question that could entail therapeutic implications.5 Only a few studies have been published about the natural history of WCH; some of them have found a higher frequency of progression to SEH compared with that of normotensive subjects.6,7
Endothelial dysfunction (ED) is considered an early event in the development of atherosclerosis,8 and several studies have demonstrated that ED is present in patients with essential hypertension.9 However, the presence of ED in patients with WCH has not been studied. ED was first studied by measuring the increase of the diameter of coronary arteries after intravenous infusion of acetylcholine; the absence of vasodilation in response to acetylcholine was considered a marker of ED.10 More recent publications studied ED by measuring vasodilation in response to acetylcholine in brachial or femoral arteries with plethysmography.11 Nowadays, noninvasive methods based on flow-mediated dilation (FMD) after the compression of the arterial wall with a pneumatic tourniquet have been validated for the study of ED, and they are used in most recent works.12
The aim of this study is to evaluate with a noninvasive method the presence of ED in patients with WCH. We intend to evaluate the variation in the diameter of the brachial artery produced by FMD after a mechanical stimulus in patients with recently diagnosed mild to moderate SEH without any previous antihypertensive treatment compared with patients with WCH and to a control group, by means of echography.
| Methods |
|---|
|
|
|---|
Subjects
Subjects were outpatients age >18 years with recent diagnosis of arterial hypertension. A control group of healthy normotensive volunteers was also included. Inclusion criteria were as follows: (1) suspected essential hypertension and no previous antihypertensive treatment, (2) diagnosis of mild to moderate hypertension according to the World Health Organization criteria,13 and (3) written informed consent. Exclusion criteria were as follows: (1) secondary hypertension; (2) personal history of cerebrovascular events, coronary artery disease, or diabetes mellitus; (3) body mass index (BMI) >30; (4) smoking; (5) serum creatinine >159.12 µmol/L, total cholesterol >6.24 mmol/L, or triglycerides >1.97 mmol/L; and (6) target-organ damage owing to hypertension.
Stratification
Patients underwent ABPM with Spacelabs 90207. BP was measured every 20 minutes during daytime and every 40 minutes during nighttime. According to the results of ABPM, patients were classified into a group of mild to moderate SEH or a group of WCH. Following the criteria of Report VI of the Joint National Committee,14 WCH was diagnosed if average daytime ambulatory systolic BP was <135 mm Hg and diastolic BP was <85 mm Hg. BP measurements were divided in daytime (between 10:00 AM and 8:00 PM) and nighttime (between midnight and 6:00 AM). Patients were classified as nondippers when the difference between average daytime BP and average nighttime BP was <10%.15 BMI
25 and <30 was considered overweight, and BMI <25 was considered normal. Blood samples were obtained for determinations of glucose, total cholesterol, and creatinine. Microalbuminuria was defined as albumin concentration between 20 and 200 µg/min in a urinary sample collected from 11:00 PM to 7:00 AM. The overall cardiovascular risk score was calculated according to the Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.16
Procedure
Vascular ultrasound scans were performed according to the method described by Celermajer et al8 with modification17 for noninvasive determination of ED. Arterial diameter was measured with a SSH-140 HG Toshiba ultrasound machine. Ultrasound images were recorded on videotape. Flow increase was induced by inflation of a pneumatic tourniquet placed 10 cm above the elbow to 300 mm Hg for 4 minutes. Diameter of right brachial artery was measured basally and 60 seconds after cuff deflation. Diameter changes were expressed as the percentage change relative to the average baseline scan. Video images were analyzed separately by 2 radiologists unaware of the patients clinical details. Diameter changes
5% at 60 seconds were considered a deficient FMD. Interassay variability was <2%.
Statistical Analysis
Data were analyzed using the statistical program SPSS version 10.0. All data in the text are expressed as mean±SD. Univariate analysis was performed by use of parametric tests. Overall differences between groups in age, cholesterol, creatinine, glycemia, BMI, and differences in results of brachial artery studies were compared by use of ANOVA test. The variables that showed significant differences with the ANOVA test were compared afterward between each group by use of Bonferroni test for multiple comparisons. Measures of ABPM were compared between the group with WCH and the control group by Students t test. The correlations between variables were determined by use of the Spearman and Pearson correlation coefficient. P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
1 exclusion criteria. A total of 29 patients, who signed informed consent, were selected for the study. Fifteen healthy volunteers were also included. After ABPM, 15 patients were classified with SEH and 14 patients with WCH. Characteristics of the 3 groups are shown in Table 1. No differences were found in the male/female ratio between the 3 groups. Although mean age of the normotensive group was slightly lower than that of the SEH and WCH groups, this difference had no statistical significance. The proportion of patients who were overweight was higher in the group with WCH, but this difference was not statistically significant. No significant differences were found between mean total cholesterol concentrations of the 3 groups. Average serum glucose levels were higher in the groups with SEH and WCH compared with the control group, but these differences were statistically significant only when comparing SEHs and normotensives. Average serum creatinine was significantly higher only in the WCH group compared with normotensives. Four patients had microalbuminuria (2 with SEH, 2 with WCH, none among controls). The overall cardiovascular risk scores calculated for the 3 groups are showed in Table 2.
|
|
Results of ABPM are shown in Table 3. Average systolic daytime BP and average systolic nighttime BP measured during ABPM was higher in the group with WCH compared with the control group. No significant differences were found in average diastolic BP. Results of ABPM were not compared between the SEH group and the WCH group because these are different by definition. Seven out of 29 (24%) patients with mild to moderate hypertension were classified as nondippers. Six patients (40%) of the SEH group followed the nondipper pattern, whereas in the WCH group only 1 subject (7%) was classified as nondipper.
|
Brachial artery studies are shown in Table 4. Basal brachial artery diameter and diameter at 60 seconds after cuff deflation (FMD) did not differ significantly between the 3 groups. Diameter increase at 60 seconds after cuff deflation was higher in the control group compared with both hypertensive groups, but no significant differences were found between SEH and WCH groups (Figure). The simple correlation analysis showed a negative correlation between basal brachial artery diameter and FMD (r=-0.534; P=0.001). This correlation was not observed in the results per groups. Neither the differences between serum glucose and creatinine levels nor the percentage of nondippers had any effect on FMD. Deficient FMD was found in both hypertensive groups, with no significant differences between both groups. None of the patients in the control group had deficient FMD.
|
|
| Discussion |
|---|
|
|
|---|
The discovery of endothelial function as a regulator of cardiovascular tone and structure, and the description of mediators such as NO originated many research works over the past decade.23 ED is defined by the production of vasospasm, vasoconstriction, platelet aggregation, thrombosis, inflammation, and increased vascular proliferation. Several studies found that ED is a marker of the development of atherosclerosis;8 this finding is probably related to the unbalance of endothelial factors, caused by a predominance of proatherosclerotic endothelial factors over the ones that promote antiatherosclerotic phenomena. Many reports have also demonstrated that the presence of ED is associated to cardiovascular risk factors such as diabetes mellitus,24 hypertriglyceridemia,25 smoking,26 hyperhomocysteinemia,27 and even alcoholism28 and mental stress.29 ED has been also demonstrated both in coronary and peripheral circulation of patients with SEH.9,30 Our study found that subjects with SEH and WCH showed similar FMD 60 seconds after stimulus, and these were lower than FMD of healthy controls; ie, patients with SEH and WCH showed more intense ED than did the control group.
The fact that no significant differences were found between the ages of the 3 groups in our study is important because several studies have demonstrated that the impairment of endothelial-dependent arterial vasodilation increases with age.31 This impairment is specially evident in subjects >65 years of age,32 but it can be detected from 40 years of age both in healthy subjects and patients with SEH.33 The proportion of patients who were overweight was lower among the SHE group than among the WCH group, although this difference was not statistically significant. This may probably be because patients with SEH who were overweight also had other associated cardiovascular risk factors, and therefore, they were excluded from the study. However, a previous work found no association between BMI and FMD in the brachial artery.34 The 3 groups had similar cholesterol levels and BMI. Although creatinine was different between the WCH group and normotensives, and serum glucose was different between the SEH group and normotensives, no significant relation was found between diameter changes at 60 seconds and glucose or creatinine levels. No differences in the overall cardiovascular risk scores could be studied between the groups.
The percentage of nondippers in both hypertensive groups was similar to the prevalence of nondippers among the hypertensive population.35 Although the percentage of nondippers was higher in the SHE group than in the WCH group, this difference did not have any effect in the FMD. The fact that ABPM results were different between the WCH group and healthy controls is noteworthy (average daytime and nighttime measures being higher in the WCH group than in healthy controls), and this finding highlights that both populations should be considered separately. Patients with WCH are probably closer to patients with SEH than to normotensives, even though by definition average daytime ABPM readings in WCH are different than those in SEH.
Our study shows that subjects with WCH have ED that is similar to that of patients with SEH and higher than that of the control group by means of the noninvasive method described by Celermajer et al.8 This method, based on FMD, has been developed over the past decade as a reproducible noninvasive technique for the study of ED, and it is nowadays the most widely used. In our study, the cuff was placed above the transducer, which induces more hyperemia and vasodilation.12,17 This method has been used in recent reports.36,37 When the interpretation of hyperemic response is performed by experimented radiologists, the interobserver variability coefficient is small,38 and the results are correlated with invasive tests bases on acetylcholine infusion.39 This method has also been used as a screening test for coronary artery disease,40 and to evaluate improvement on ED in recent studies over therapeutic interventions in patients with SEH.36
Several studies have found a negative correlation between basal arterial diameter and FMD: subjects with higher basal arterial diameter have lower FMD.41 Our patients with WCH had lower basal arterial diameters compared with those of the other 2 groups, but this difference was not statistically significant. The overall analysis of our patients showed also that patients with higher brachial artery diameter at rest had lower FMD. However, this correlation was not observed when each group was analyzed separately. Moreover, the proportion of deficient vasodilatory responses defined as diameter increases
5% at 60 seconds was noteworthy both in the SEH (26.7%) and WCH (42.9%) groups. None of the subjects from the control group had diameter changes
5%. We have found a high variability of the results of the diameter increase at 60 seconds; this variability is similar to that found in other studies, which showed high SDs in the distribution of this variable.
A limitation of our study is the possibility that the subjects studied might not be representative of the populations with mild to moderate SEH and WCH. Because of the exclusion criteria, our subjects might only be representative of a group of nonsmoking, nondiabetic, normocholesterolemic patients with no history of cardiovascular complications and not of the whole population. Besides, our series is small because patients who fulfill the inclusion criteria (recent diagnosis of mild to moderate hypertension without previous antihypertensive treatment and without other cardiovascular risk factors) are usually evaluated by primary care doctors and are less frequently referred to a tertiary hospital. The fact that patients with WCH have a similar ED to that of patients with SEH suggests that this group of patients have an increased probability of developing atherosclerosis and also a greater cardiovascular risk compared with normotensive subjects, and supports previous works that questioned whether WCH be considered a innocent trait and that made it comparable to SEH. ED in WCH group also explains the high incidence of progression to SEH over the years in this group of patients. Two recent works have demonstrated that subjects with BP levels that are considered normal (120 to 129/80 to 84 mm Hg) or high-normal (130 to 139/85 to 89 mm Hg) have a high rate of progression to SEH over a 4-year period,42 and also that patients with high-normal BP have an increased cardiovascular risk which is greater than subjects with optimal BP.43 Because there is an inverse relation between BP levels and NO vascular action, it is probable that ED might be present in subjects with normal-high BP, and this would explain the increased cardiovascular risk among this group.44 We may as well assume that because ED is present in patients with WCH, they have an increased cardiovascular risk, which would be similar to that of patients with SEH. Whether subjects with WCH, as well as the ones with high-normal BP, could have a benefit if they received similar therapeutic approaches as those with SEH is still an unsolved question that must be demonstrated in future works, even though recent data support this hypothesis. In conclusion, our study shows that FMD is similar in WCH patients and mild to moderate hypertensives.
Perspectives
The presence of ED among WCH subjects, in the same degree as in SHE subjects, suggests that this group of patients has early atherosclerosis and therefore an increased cardiovascular risk. Our results support previous works that found organic damage in WCH, and they are consistent with the higher cardiovascular morbidity and progression to SEH that have been found in this group of patients. Because several pharmacological therapies have been shown to improve ED in SEH patients, patients with WCH might benefit from pharmacological treatment to improve ED and therefore prevent early atherosclerosis. More studies are needed to find out whether antihypertensive treatment would decrease cardiovascular morbidity and mortality in WCH patients, and to investigate the potential role of the different antihypertensive drugs in improving ED in this group of patients.
| Acknowledgments |
|---|
Received March 26, 2002; first decision April 26, 2002; accepted July 10, 2002.
| References |
|---|
|
|
|---|
2. Pickering TG. Clinical applications of ambulatory blood pressure monitoring: the white coat syndrome. Clin Invest Med. 1991; 14: 212217.[Medline] [Order article via Infotrieve]
3. Pierdomenico SD, Mezzetti A, Lapenna D, Guglielmi MD, Mancini M, Salvatore L, Antidormi T, Costantini F, Cuccurullo F. White-coat hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J. 1995; 16: 692697.
4. Martínez MA, García-Puig J, Martín JC, Guallar-Castillon P, Aguirre dC, Torre A, Armada E, Nevado A, Madero RS. Frequency and determinants of white coat hypertension in mild to moderate hypertension: a primary care-based study: Monitorizacion Ambulatoria de la Presion Arterial (MAPA)area 5 working group. Am J Hypertens. 1999; 12: 251259.[CrossRef][Medline] [Order article via Infotrieve]
5. Kuwajima I, Suzuki Y, Fujisawa A, Kuramoto K. Is white coat hypertension innocent?: structure and function of the heart in the elderly. Hypertension. 1993; 22: 826831.
6. Polonia J, Santos A, Gama GM, Basto F, Bettencourt P, Martins LR. Follow-up clinic and ambulatory blood pressure in untreated white coat hypertensive patients: evaluation after 2 to 5 years. Blood Press Monit. 1997; 2: 289295.[Medline] [Order article via Infotrieve]
7. Strandberg TE, Salomaa V. White coat effect, blood pressure and mortality in men: prospective cohort study. Eur Heart J. 2000; 21: 17141718.
8. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Owen IM, Sullivan ID, Lloyd JK. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 11111115.[CrossRef][Medline] [Order article via Infotrieve]
9. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990; 323: 2227.[Abstract]
10. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986; 315: 10461051.[Abstract]
11. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol. 1994; 23: 16101616.[Abstract]
12. Vogel RA. Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol. 2001; 88: 31E34E.[Medline] [Order article via Infotrieve]
13. WHO Expert Committee on Hypertension Control. Hypertension Control: Report of a WHO Expert Committee. WHO Technical Report Series No. 862. Geneva, Switzerland: 1999.
14. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157: 24132446.
15. Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. J Hypertens. 1991; 9 (suppl): S42S44.[CrossRef]
16. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994; 15: 13001331.
17. Mannion TC, Vita JA, Keaney JF Jr, Benjamin EJ, Hunter L, Polak JF. Non-invasive assessment of brachial artery endothelial vasomotor function: the effect of cuff position on level of discomfort and vasomotor responses. Vasc Med. 1998; 3: 263267.
18. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation. 1998; 98: 18921897.
19. Muldoon MF, Nazzaro P, Sutton-Tyrrell K, Manuck SB. White-coat hypertension and carotid artery atherosclerosis: a matching study. Arch Intern Med. 2000; 160: 15071512.
20. Pose-Reino A, González-Juanatey JR, Pastor C, Méndez I, Estévez JC, Álvarez D, Valdés L, Cabezas-Cerrato J. Clinical implications of white coat hypertension. Blood Press. 1996; 5: 264273.[Medline] [Order article via Infotrieve]
21. Gosse P, Promax H, Durandet P, Clementy J. White coat hypertension: no harm for the heart. Hypertension. 1993; 22: 766770.
22. Verdecchia P. White-coat hypertension in adults and children. Blood Press Monit. 1999; 4: 175179.[Medline] [Order article via Infotrieve]
23. Palmer RMJ, Ferridge AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327: 524526.[CrossRef][Medline] [Order article via Infotrieve]
24. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia. 2001; 44: 593601.[CrossRef][Medline] [Order article via Infotrieve]
25. Bae JH, Bassenge E, Kim KB, Kim YN, Kim KS, Lee HJ, Moon KC, Lee MS, Park KY, Schwemmer M. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis. 2001; 155: 517523.[CrossRef][Medline] [Order article via Infotrieve]
26. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation. 2001; 104: 19051910.
27. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocystinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997; 96: 25422544.
28. Maiorano G, Bartolomucci F, Contursi V, Minenna FS, Di Mise R, Palasciano A, Allegrini B, Amoruso M, Kozakova M. Noninvasive detection of vascular dysfunction in alcoholic patients. Am J Hypertens. 1999; 12: 137144.[Medline] [Order article via Infotrieve]
29. Ghiadoni L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M, OConnor G, Betteridge J, Klein N, Steptoe A, Deanfield JE. Mental stress induces transient endothelial dysfunction in humans. Circulation. 2000; 102: 24732478.
30. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon ROIII. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995; 91: 17321738.
31. Andrawis N, Jones DS, Abernethy DR. Aging is associated with endothelial dysfunction in the human forearm vasculature. J Am Geriatr Soc. 2000; 48: 193198.[Medline] [Order article via Infotrieve]
32. Giordano G, Guarini P, Giordano A, Ferraro P, Supino P, Lionetti F, Vastano L, Giordano B, Vigorito C, Rengo F. Reduced endothelium-dependent peripheral vasodilation in the aged. Cardiologia. 1995; 40: 4750.[Medline] [Order article via Infotrieve]
33. Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996; 27: 849853.
34. Schroeder S, Enderle MD, Baumbach A, Ossen R, Herdeg C, Kuettner A, Karsch KR. Influence of vessel size, age and body mass index on the flow-mediated dilatation (FMD%) of the brachial artery. Int J Cardiol. 2000; 76: 219225.[CrossRef][Medline] [Order article via Infotrieve]
35. White WB, Mansoor GA, Tendler BE, Anwar YA. Nocturnal blood pressure epidemiology, determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998; 3: 4351.[Medline] [Order article via Infotrieve]
36. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, Brun C, Agabiti-Rosei E. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension. 1999; 33: 575580.
37. Berger R, Stanek B, Hulsmann M, Frey B, Heher S, Pacher R, Neunteufl T. Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure. Circulation. 2001; 103: 981986.
38. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J. 1995; 74: 247253.
39. Irace C, Ceravolo R, Notarangelo L, Crescenzo A, Ventura G, Tamburrini O, Perticone F, Gnasso A. Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound. Atherosclerosis. 2001; 158: 5359.[CrossRef][Medline] [Order article via Infotrieve]
40. Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, Pfohl M, Herdeg C, Oberhoff M, Haering HU, Karsch KR. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J. 1999; 138: 731739.[CrossRef][Medline] [Order article via Infotrieve]
41. Uehata A, Lieberman EH, Gerhard MD, Anderson TJ, Ganz P, Polak JF, Creager MA, Yeung AC. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med. 1997; 2: 8792.[Medline] [Order article via Infotrieve]
42. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 358: 16821686.[CrossRef][Medline] [Order article via Infotrieve]
43. Vasan RS, Larson MG, Leip EP, Evans JC, ODonnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001; 345: 12911297.
44. Panza JA. High-normal blood pressure more high than normal. N Engl J Med. 2001; 345: 13371339.
This article has been cited by other articles:
![]() |
E. Urbina, B. Alpert, J. Flynn, L. Hayman, G. A. Harshfield, M. Jacobson, L. Mahoney, B. McCrindle, M. Mietus-Snyder, J. Steinberger, et al. Ambulatory Blood Pressure Monitoring in Children and Adolescents: Recommendations for Standard Assessment: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young and the Council for High Blood Pressure Research Hypertension, September 1, 2008; 52(3): 433 - 451. [Full Text] [PDF] |
||||
![]() |
J. J. R. Blanco, I. S. Garcia, J. G. Cerezo, J. M. P. S. de Rivera, P. M. Anaya, P. G. Raya, J. G. Garcia, J. R. A. Lopez, F. J. B. Hernandez, and J. J. V. Rodriguez Endothelial function in HIV-infected patients with low or mild cardiovascular risk J. Antimicrob. Chemother., July 1, 2006; 58(1): 133 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Dyson, J. K. Shoemaker, and R. L. Hughson Effect of acute sympathetic nervous system activation on flow-mediated dilation of brachial artery Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1446 - H1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. White Jr. and J. Schick Home Blood Pressure Monitoring and Diabetes Clin. Diabetes, January 1, 2004; 22(1): 28 - 31. [Full Text] [PDF] |
||||
![]() |
Doc, My Blood Pressure Is High Only When I See You. Do I Have to Worry? Journal Watch Cardiology, November 22, 2002; 2002(1122): 2 - 2. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |